PT1583562E - Angiopep-1, compostos relacionados, e suas utilizações - Google Patents

Angiopep-1, compostos relacionados, e suas utilizações Download PDF

Info

Publication number
PT1583562E
PT1583562E PT04700102T PT04700102T PT1583562E PT 1583562 E PT1583562 E PT 1583562E PT 04700102 T PT04700102 T PT 04700102T PT 04700102 T PT04700102 T PT 04700102T PT 1583562 E PT1583562 E PT 1583562E
Authority
PT
Portugal
Prior art keywords
blood
brain barrier
carrier
relates
agent
Prior art date
Application number
PT04700102T
Other languages
English (en)
Portuguese (pt)
Inventor
Richard Beliveau
Michel Demeule
Original Assignee
Angiochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiochem Inc filed Critical Angiochem Inc
Publication of PT1583562E publication Critical patent/PT1583562E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
PT04700102T 2003-01-06 2004-01-05 Angiopep-1, compostos relacionados, e suas utilizações PT1583562E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43798603P 2003-01-06 2003-01-06

Publications (1)

Publication Number Publication Date
PT1583562E true PT1583562E (pt) 2011-09-19

Family

ID=32713262

Family Applications (1)

Application Number Title Priority Date Filing Date
PT04700102T PT1583562E (pt) 2003-01-06 2004-01-05 Angiopep-1, compostos relacionados, e suas utilizações

Country Status (15)

Country Link
US (1) US9221867B2 (enExample)
EP (2) EP1583562B1 (enExample)
JP (2) JP4903036B2 (enExample)
CN (2) CN1747747B (enExample)
AT (1) ATE512674T1 (enExample)
AU (2) AU2004203682B2 (enExample)
BR (1) BRPI0406647A (enExample)
CA (1) CA2516056C (enExample)
CY (1) CY1111844T1 (enExample)
DK (1) DK1583562T3 (enExample)
ES (1) ES2368941T3 (enExample)
MX (1) MXPA05007322A (enExample)
PT (1) PT1583562E (enExample)
SI (1) SI1583562T1 (enExample)
WO (1) WO2004060403A2 (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1583562T3 (da) * 2003-01-06 2011-09-19 Angiochem Inc Angiopep-1, beslægtede forbindelser og anvendelser deraf
EP1841455A1 (en) 2005-01-24 2007-10-10 Amgen Inc. Humanized anti-amyloid antibody
PT2360258E (pt) * 2005-02-18 2015-01-13 Angiochem Inc Moléculas para transportar um composto através da barreira hematoencefálica
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
DK2233156T3 (da) * 2005-07-15 2013-08-05 Angiochem Inc Anvendelse af aprotininpolypeptider som bærere i farmaceutiske konjugater
JP4945766B2 (ja) * 2006-01-24 2012-06-06 国立大学法人 鹿児島大学 脳神経細胞への薬物の標的化剤
US20090239942A1 (en) * 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
US8487072B2 (en) 2006-10-19 2013-07-16 Angiochem Inc. Compounds for stimulating P-glycoprotein function and uses thereof
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
PL2164866T3 (pl) * 2007-05-29 2014-10-31 Angiochem Inc Polipeptydy podobne do aprotyniny do dostarczania skoniugowanych z nimi środków do tkanek
JP5844971B2 (ja) * 2007-05-29 2016-01-20 アンジオケム，インコーポレーテッド コンジュゲートされた物質を組織に送達するためのアプロチニン様ポリペプチド
WO2009085200A2 (en) 2007-12-21 2009-07-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
BRPI0910557A2 (pt) 2008-04-18 2015-09-29 Angiochem Inc composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e uso.
US10272178B2 (en) 2008-04-29 2019-04-30 Virginia Tech Intellectual Properties Inc. Methods for blood-brain barrier disruption using electrical energy
US10117707B2 (en) 2008-04-29 2018-11-06 Virginia Tech Intellectual Properties, Inc. System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies
US10245098B2 (en) 2008-04-29 2019-04-02 Virginia Tech Intellectual Properties, Inc. Acute blood-brain barrier disruption using electrical energy based therapy
US8992517B2 (en) 2008-04-29 2015-03-31 Virginia Tech Intellectual Properties Inc. Irreversible electroporation to treat aberrant cell masses
US9198733B2 (en) 2008-04-29 2015-12-01 Virginia Tech Intellectual Properties, Inc. Treatment planning for electroporation-based therapies
US11254926B2 (en) 2008-04-29 2022-02-22 Virginia Tech Intellectual Properties, Inc. Devices and methods for high frequency electroporation
EP2280741A4 (en) 2008-04-29 2012-06-13 Virginia Tech Intell Prop IRREVERSIBLE ELECTROPORATION FOR THE PRODUCTION OF TISSUE OBJECTS
US11272979B2 (en) 2008-04-29 2022-03-15 Virginia Tech Intellectual Properties, Inc. System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies
US10238447B2 (en) 2008-04-29 2019-03-26 Virginia Tech Intellectual Properties, Inc. System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress
US9283051B2 (en) 2008-04-29 2016-03-15 Virginia Tech Intellectual Properties, Inc. System and method for estimating a treatment volume for administering electrical-energy based therapies
US10702326B2 (en) 2011-07-15 2020-07-07 Virginia Tech Intellectual Properties, Inc. Device and method for electroporation based treatment of stenosis of a tubular body part
US9867652B2 (en) 2008-04-29 2018-01-16 Virginia Tech Intellectual Properties, Inc. Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds
RU2531591C2 (ru) * 2008-10-15 2014-10-20 Ангиокем Инк. Конъюгаты этопозида и доксорубицина для доставки лекарственных средств
RU2011118056A (ru) 2008-10-15 2012-11-27 Ангиокем Инк. Конъюгаты агонистов glp-1 и их применение
CN102307904A (zh) 2008-12-05 2012-01-04 安吉奥开米公司 神经降压素或神经降压素类似物的缀合物及其用途
AU2009327267A1 (en) 2008-12-17 2011-07-14 Angiochem, Inc. Membrane type-1 matrix metalloprotein inhibitors and uses thereof
DE102009006228A1 (de) 2009-01-27 2010-07-29 Epo Experimentelle Pharmakologie & Onkologie Berlin-Buch Gmbh Liposomale Zusammensetzung zur Behandlung von Hirnmetastasen
US8632534B2 (en) 2009-04-03 2014-01-21 Angiodynamics, Inc. Irreversible electroporation (IRE) for congestive obstructive pulmonary disease (COPD)
US11382681B2 (en) 2009-04-09 2022-07-12 Virginia Tech Intellectual Properties, Inc. Device and methods for delivery of high frequency electrical pulses for non-thermal ablation
US11638603B2 (en) 2009-04-09 2023-05-02 Virginia Tech Intellectual Properties, Inc. Selective modulation of intracellular effects of cells using pulsed electric fields
CA2759129C (en) 2009-04-20 2018-12-11 Angiochem Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
WO2010138919A2 (en) 2009-05-28 2010-12-02 Angiodynamics, Inc. System and method for synchronizing energy delivery to the cardiac rhythm
US9895189B2 (en) 2009-06-19 2018-02-20 Angiodynamics, Inc. Methods of sterilization and treating infection using irreversible electroporation
US9161988B2 (en) 2009-07-02 2015-10-20 Angiochem Inc. Multimeric peptide conjugates and uses thereof
EP3144670B1 (en) * 2009-10-30 2018-10-03 Keio University Anticancer agent sensitivity-determining marker
CA2803646A1 (en) * 2010-07-02 2012-01-05 Angiochem Inc. Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
WO2012051433A2 (en) 2010-10-13 2012-04-19 Angiodynamics, Inc. System and method for electrically ablating tissue of a patient
WO2012088149A2 (en) 2010-12-20 2012-06-28 Virginia Tech Intellectual Properties, Inc. High-frequency electroporation for cancer therapy
EP2682401A4 (en) * 2011-02-02 2015-06-03 Microbial Chem Res Found FOR OBTAINING THE BLOOD-BRAIN-DISABLED MEDICAMENT OUTPUT MATERIAL, PEPTIDE THEREOF AND USE THEREOF
US9078665B2 (en) 2011-09-28 2015-07-14 Angiodynamics, Inc. Multiple treatment zone ablation probe
US9414881B2 (en) 2012-02-08 2016-08-16 Angiodynamics, Inc. System and method for increasing a target zone for electrical ablation
CA2881602A1 (en) 2012-08-14 2014-02-20 Angiochem Inc. Peptide-dendrimer conjugates and uses thereof
US9888956B2 (en) 2013-01-22 2018-02-13 Angiodynamics, Inc. Integrated pump and generator device and method of use
AU2014243816B2 (en) * 2013-03-13 2019-01-31 Bioasis Technologies Inc. Fragments of p97 and uses thereof
WO2015031673A2 (en) 2013-08-28 2015-03-05 Bioasis Technologies Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
SG10201902074UA (en) 2013-10-04 2019-04-29 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
CN113616656B (zh) 2014-03-19 2023-02-17 无限药品股份有限公司 用于治疗PI3K-γ介导的障碍的杂环化合物
JP6594901B2 (ja) 2014-05-12 2019-10-23 バージニア テック インテレクチュアル プロパティース インコーポレイテッド パルス電界を使用した細胞の細胞内効果の選択的調節
US12114911B2 (en) 2014-08-28 2024-10-15 Angiodynamics, Inc. System and method for ablating a tissue site by electroporation with real-time pulse monitoring
CN105585614B (zh) * 2014-10-24 2019-06-07 中国科学技术大学 用于淀粉样蛋白显像的血管肽及其衍生物
EP3222291B1 (en) * 2014-10-24 2020-08-19 University of Science and Technology of China Angiopeptin conjugates for amyloid protein targeting
US10694972B2 (en) 2014-12-15 2020-06-30 Virginia Tech Intellectual Properties, Inc. Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment
DK3307326T3 (da) 2015-06-15 2020-10-19 Angiochem Inc Fremgangsmåder til behandling af leptomeningeal karcinomatose
US11207461B2 (en) 2015-07-30 2021-12-28 Anoop U. R Drug delivery system and method for controlled and continuous delivery of drugs into the brain by bypassing the blood brain barrier
AU2016322552B2 (en) 2015-09-14 2021-03-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
CN106188308B (zh) * 2016-07-12 2019-08-20 西安医学院 一种跨血脑屏障蛋白转运体及制备方法和应用
US10905492B2 (en) 2016-11-17 2021-02-02 Angiodynamics, Inc. Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode
WO2018226992A1 (en) 2017-06-07 2018-12-13 Adrx, Inc. Tau aggregation inhibitors
EP3668886A2 (en) 2017-08-18 2020-06-24 Adrx, Inc. Tau aggregation peptide inhibitors
US11607537B2 (en) 2017-12-05 2023-03-21 Virginia Tech Intellectual Properties, Inc. Method for treating neurological disorders, including tumors, with electroporation
US10688191B2 (en) 2018-01-19 2020-06-23 Hr Biomed, Llc Delivery of a chemotherapy agent across the blood-brain barrier
CN111867573A (zh) 2018-01-29 2020-10-30 科诺斯治疗学公司 硼替佐米的瘤内递送
US11311329B2 (en) 2018-03-13 2022-04-26 Virginia Tech Intellectual Properties, Inc. Treatment planning for immunotherapy based treatments using non-thermal ablation techniques
US12390262B2 (en) 2018-03-13 2025-08-19 Virginia Tech Intellectual Properties, Inc. Treatment planning system for immunotherapy enhancement via non-thermal ablation
US11925405B2 (en) 2018-03-13 2024-03-12 Virginia Tech Intellectual Properties, Inc. Treatment planning system for immunotherapy enhancement via non-thermal ablation
US10842755B2 (en) 2018-03-23 2020-11-24 University Of South Carolina Nanoparticles for brain targeted drug delivery
US11950835B2 (en) 2019-06-28 2024-04-09 Virginia Tech Intellectual Properties, Inc. Cycled pulsing to mitigate thermal damage for multi-electrode irreversible electroporation therapy
US12214189B2 (en) 2019-07-24 2025-02-04 Virginia Tech Intellectual Properties, Inc. Fourier analysis spectroscopy for monitoring tissue impedance changes and treatment outcome during electroporation-based-therapies
CA3128035A1 (en) 2020-08-13 2022-02-13 Bioasis Technologies, Inc. Combination therapies for delivery across the blood brain barrier
US12485279B2 (en) 2020-11-25 2025-12-02 Virginia Tech Intellectual Properties, Inc. Methods for modulating temporal infrastructure of pulsed electric fields

Family Cites Families (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
EP0260306A4 (en) 1986-03-13 1990-09-26 Biotechnology Pty Ltd Method of assay of inhibin
US4902505A (en) * 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4904768A (en) * 1987-08-04 1990-02-27 Bristol-Myers Company Epipodophyllotoxin glucoside 4'-phosphate derivatives
GB2208511A (en) * 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US5632990A (en) 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
US5258499A (en) * 1988-05-16 1993-11-02 Vestar, Inc. Liposome targeting using receptor specific ligands
US5028697A (en) * 1988-08-08 1991-07-02 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
US5169933A (en) 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5948634A (en) * 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
DE3912638A1 (de) 1989-04-18 1990-10-31 Bayer Ag Gentechnologisch hergestellte homologe des alzheimer protease inhibitors, wirtstaemme sowie expressionsvektoren fuer ihre herstellung und ihre verwendung als arzneimittel
US5126249A (en) * 1989-05-09 1992-06-30 Eli Lilly And Company Enzymatic removal of a protein amino-terminal sequence
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US6475781B1 (en) 1990-05-17 2002-11-05 Dana-Farber Cancer Institute, Inc. Trans-dominant suppressor genes for oligomeric proteins
GB9017008D0 (en) 1990-08-02 1990-09-19 Erba Carlo Spa Process for the enzymatic preparation of basic fibroblast growth factor
US5714167A (en) * 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
JPH07108232B2 (ja) * 1990-10-09 1995-11-22 エム・ディ・リサーチ株式会社 ペプチド又は蛋白質の製造方法
US6495513B1 (en) 1991-03-11 2002-12-17 Curis, Inc. Morphogen-enhanced survival and repair of neural cells
US5955444A (en) * 1991-08-09 1999-09-21 Massachusetts Institute Of Technology Method of inhibiting abnormal tau hyper phosphorylation in a cell
US5627270A (en) * 1991-12-13 1997-05-06 Trustees Of Princeton University Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5204354A (en) * 1992-02-14 1993-04-20 Merck & Co., Inc. Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders
GB9213077D0 (en) * 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
JPH08504568A (ja) * 1992-09-25 1996-05-21 コルバス・インターナショナル、インコーポレイテッド ウシ膵トリプシン阻害因子から誘導される因子ＶＩＩａ−組織因子複合体の阻害因子
EP0599303A3 (en) * 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Peptide conjugate
WO1994019692A1 (en) * 1993-02-18 1994-09-01 The General Hospital Corporation Alzheimer's disease therapeutics
WO1996031531A2 (en) * 1995-04-04 1996-10-10 Advanced Bioconcept, Inc. Fluorescent peptides
AU5854096A (en) 1995-05-08 1996-11-29 Scios Inc. Kunitz type protease inhibitors
ZA963619B (en) * 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
WO1996039183A1 (en) 1995-05-31 1996-12-12 Fred Hutchinson Cancer Research Center Compositions and methods for targeted delivery of effector molecules
US5780265A (en) * 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
WO1996040210A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
JP3469584B2 (ja) * 1996-03-11 2003-11-25 バイエル コーポレイション ヒト ビクニン
WO1997040160A1 (en) 1996-04-24 1997-10-30 Rijksuniversiteit Te Groningen A prokaryotic protein having functional and structural homology with the human p-glycoprotein encoded by the mdr-1 gene, nucleic acids encoding and cells expressing said protein
AU729643B2 (en) 1996-05-01 2001-02-08 Antivirals Inc. Polypeptide conjugates for transporting substances across cell membranes
DE19636889A1 (de) * 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
EP0932390A1 (en) 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US5948750A (en) * 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
DE69838544T2 (de) 1997-03-04 2008-07-24 Savient Pharmaceuticals, Inc. Isolierung von gewebespezifischen peptidliganden und ihre verwendung zur ausrichtung von pharmazeutika auf zielorgane
US6126965A (en) * 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
GB9705903D0 (en) * 1997-03-21 1997-05-07 Elliott Gillian D VP22 Proteins and uses thereof
ES2210761T3 (es) * 1997-05-21 2004-07-01 The Board Of Trustees Of The Leland Stanford Junior University Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas.
US6391305B1 (en) * 1997-09-10 2002-05-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6093692A (en) * 1997-09-25 2000-07-25 The University Of Southern California Method and compositions for lipidization of hydrophilic molecules
US6475481B2 (en) 1997-11-18 2002-11-05 Canji Inc Purging of stem cell products
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
ES2274621T3 (es) 1998-03-12 2007-05-16 Georgetown University Peptidos que contienen una secuencia de reconocimiento del colesterol y usos de los mismos.
US5981564A (en) 1998-07-01 1999-11-09 Universite Laval Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
JP4808846B2 (ja) * 1999-02-24 2011-11-02 ザ ユーエイビー リサーチ ファンデイション 癌の標的付けられた治療のためのタキサン誘導体
US6138375A (en) * 1999-03-01 2000-10-31 Gala Industries, Inc. Support ring for pellet dryer screen
US6713454B1 (en) * 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
PT1214292E (pt) * 1999-09-24 2007-09-14 Genentech Inc Derivados de tirosina
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
DE19953696A1 (de) * 1999-11-09 2001-05-10 Alexander Cherkasky Selektive proteolytische Synzyme (SPS)
DE19953966A1 (de) * 1999-11-09 2001-05-10 Leica Microsystems Verfahren und Vorrichtung zur Dickenmessung an transparenten Schichten
GB2360453B (en) 2000-01-05 2004-09-01 Univ Cardiff Treatment of skin conditions
US20020086384A1 (en) * 2000-03-14 2002-07-04 Zurit Levine Splice variants of oncogenes
CA2355334A1 (en) 2000-10-16 2002-04-16 Procyon Biopharma Inc. Pharmaceutical preparations and methods for inhibiting tumors
CA2421042C (en) 2000-10-20 2011-07-05 Abbott Laboratories The use of tiagabine for treatment of diabetic neuropathy and migraine
WO2002043765A2 (en) 2000-11-28 2002-06-06 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
EP1383492A4 (en) 2001-03-23 2008-12-24 Napro Biotherapeutics Inc MOLECULAR CONJUGATES FOR USE IN CANCER THERAPY
DK2322631T3 (en) 2001-04-19 2015-01-12 Scripps Research Inst Methods and compositions for the production of orthogonal tRNA-aminoacyl-tRNA syntetasepar
WO2003102583A1 (en) 2002-05-29 2003-12-11 Symbiontics, Inc. Targeted therapeutic proteins
WO2003009815A2 (en) 2001-07-25 2003-02-06 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
US7192921B2 (en) * 2001-11-08 2007-03-20 The Burnham Institute Peptides that home to tumor lymphatic vasculature and methods of using same
EP1472351B1 (en) * 2002-02-07 2007-06-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Amino acid sequences capable of facilitating penetration across a biological barrier
ATE441661T1 (de) * 2002-03-29 2009-09-15 Creagene Inc Zytoplasmatische transduktionspeptide und deren verwendungen
US6881829B2 (en) * 2002-04-26 2005-04-19 Chimeracom, L.L.C. Chimeric hybrid analgesics
JP2005537244A (ja) * 2002-06-28 2005-12-08 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド 療法化合物の粘膜搬送を増進させるための、上皮接合部接着分子の生理機能を調節する組成物および方法
US7829694B2 (en) 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US20040102369A1 (en) * 2002-11-27 2004-05-27 The Regents Of The University Of California Transport of basic fibroblast growth factor across the blood brain barrier
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US7319090B2 (en) * 2002-11-27 2008-01-15 University Of North Carolina At Chapel Hill Methods of treating cerebral ischemia
DK1583562T3 (da) * 2003-01-06 2011-09-19 Angiochem Inc Angiopep-1, beslægtede forbindelser og anvendelser deraf
US20040162284A1 (en) * 2003-02-19 2004-08-19 Harris Herbert W. Method of lowering body temperature with (S) tofisopam
EP1615655B1 (en) 2003-04-08 2012-02-22 Biotempt B.V. Use of compositions for mucosal and oral administration comprising hcg fragments
ES2366185T3 (es) 2003-04-11 2011-10-18 Institut Pasteur Vacunas de péptidos sintéticas para vih: el epítopo de cbd como un inmunógeno eficaz para provocar anticuerpos ampliamente neutralizantes contra el vih.
AU2003286870A1 (en) 2003-06-05 2005-01-04 Salk Institute For Biological Studies Targeting polypeptides to the central nervous system
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
JP5624256B2 (ja) 2003-06-20 2014-11-12 ラプター・ファーマシューティカル・インコーポレイテッド 脳および他の組織への治療化合物の送達
KR20060036476A (ko) 2003-08-08 2006-04-28 가부시키가이샤 티슈 타겟팅 쟈판 뇌 이동 활성을 가지는 폴리펩티드 및 그 이용
JP2007512001A (ja) 2003-08-28 2007-05-17 バイオレクシス ファーマシューティカル コーポレイション Ｅｐｏミメティックペプチドおよび融合タンパク質
US20050058702A1 (en) * 2003-09-17 2005-03-17 Ben-Sasson Shmuel A. Compositions capable of facilitating penetration across a biological barrier
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
US7208174B2 (en) * 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
JP2008507280A (ja) * 2004-07-21 2008-03-13 アンブレツクス・インコーポレイテツド 非天然コードアミノ酸を用いた生合成ポリペプチド
DE602005015994D1 (de) * 2004-09-29 2009-09-24 Childrens Memorial Hospital siRNA-VERMITTELTES GEN-SILENCING VON ALPHA-SYNUKLEIN
US9002652B1 (en) * 2005-01-27 2015-04-07 Institute For Systems Biology Methods for identifying and using organ-specific proteins in blood
PT2360258E (pt) * 2005-02-18 2015-01-13 Angiochem Inc Moléculas para transportar um composto através da barreira hematoencefálica
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
CN103285395A (zh) 2005-02-18 2013-09-11 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
JP5137814B2 (ja) 2005-04-06 2013-02-06 ジェンザイム・コーポレーション 治療ターゲティングのための酸不安定リンカーを介するｐｅｇおよびポリシアルリソソーム酵素のコンジュゲート
WO2006124737A2 (en) * 2005-05-12 2006-11-23 Tapestry Pharmaceuticals, Inc. Molecular constructs suitable for targeted conjugates
WO2006138343A2 (en) 2005-06-14 2006-12-28 Raptor Pharmaceutical Inc. Compositions comprising receptor - associated protein (rap) variants specific for lrp2 and uses thereof
DK2233156T3 (da) 2005-07-15 2013-08-05 Angiochem Inc Anvendelse af aprotininpolypeptider som bærere i farmaceutiske konjugater
BRPI0615562A2 (pt) * 2005-07-19 2010-01-26 Univ Illinois agentes de transporte para atravessamento da barreira sangue-cérebro e entrada nas células cancerìgenas do cérebro e métodos para o seu uso
GB0517092D0 (en) 2005-08-19 2005-09-28 Novartis Ag New compositions containing taxane derivatives
CA2621694A1 (en) 2005-09-08 2007-03-15 Nastech Pharmaceutical Company Inc. Pharmaceutical compositions for delivery of ribonucleic acid to a cell
US9062126B2 (en) 2005-09-16 2015-06-23 Raptor Pharmaceuticals Inc. Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
US8142781B2 (en) 2005-10-07 2012-03-27 Armagen Technologies, Inc. Fusion proteins for blood-brain barrier delivery
US20070197460A1 (en) * 2005-11-01 2007-08-23 Alnylam Pharmaceuticals, Inc. Rnai inhibition of influenza virus replication
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
US8290433B2 (en) * 2007-11-14 2012-10-16 Blaze Mobile, Inc. Method and system for securing transactions made through a mobile communication device
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
SI2402754T2 (sl) 2006-03-06 2023-09-29 Amunix Operating Inc. Nestrukturirani rekombinantni polimeri in njihove uporabe
US7477504B1 (en) 2006-03-13 2009-01-13 C.P.D. Technologies, Inc. Versatile stun glove
DE602007003703D1 (de) 2006-03-30 2010-01-21 Glaxo Group Ltd Gegen amyloid-beta peptid gerichtete antikörper
WO2008100328A2 (en) * 2006-07-13 2008-08-21 Burnham Institute For Medical Research METHODS AND COMPOSITIONS FOR TARGETING gC1qR/p32
EP2046826B1 (en) 2006-07-24 2011-09-14 Biorexis Pharmaceutical Corporation Exendin fusion proteins
JP2010503710A (ja) 2006-09-18 2010-02-04 ラプトール ファーマシューティカル インコーポレイテッド 受容体関連タンパク質（ｒａｐ）結合体の投与による肝障害の処置
US8487072B2 (en) 2006-10-19 2013-07-16 Angiochem Inc. Compounds for stimulating P-glycoprotein function and uses thereof
US9399675B2 (en) * 2007-02-28 2016-07-26 The Board Of Regents Of The University Of Oklahoma Methods and compositions for diagnosing Alzheimer's disease and age-related macular degeneration
KR20100015786A (ko) 2007-03-21 2010-02-12 랩터 파마슈티컬 인코포레이티드 환형의 수용체-연관된 단백질(ｒａｐ) 펩티드
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
PL2164866T3 (pl) 2007-05-29 2014-10-31 Angiochem Inc Polipeptydy podobne do aprotyniny do dostarczania skoniugowanych z nimi środków do tkanek
US8802631B2 (en) * 2007-09-17 2014-08-12 Ludwig Institute For Cancer Research Ltd. Peptides and methods for the treatment of gliomas and other cancers
JP5697450B2 (ja) 2007-10-02 2015-04-08 マリーナ バイオテック，インコーポレイテッド 核酸の送達のためのリポペプチド
WO2009070597A2 (en) 2007-11-26 2009-06-04 Armagen Technologies, Inc. Fusion proteins for delivery of gdnf to the cns
EP2235175A4 (en) 2007-12-20 2012-04-25 Angiochem Inc POLYPEPTIDE-NUCLEIC ACID CONJUGATES AND USES THEREOF
US8193182B2 (en) * 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CA2713872A1 (en) 2008-02-21 2009-08-27 Burnham Institute For Medical Research Methods and compositions related to peptides and proteins with c-terminal elements
BRPI0910557A2 (pt) 2008-04-18 2015-09-29 Angiochem Inc composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e uso.
WO2010006239A2 (en) 2008-07-10 2010-01-14 The Board Of Trustees Of The University Of Illinois Regulation of apoptosis by neural specific splice variants of ig20
RU2011118056A (ru) 2008-10-15 2012-11-27 Ангиокем Инк. Конъюгаты агонистов glp-1 и их применение
RU2531591C2 (ru) 2008-10-15 2014-10-20 Ангиокем Инк. Конъюгаты этопозида и доксорубицина для доставки лекарственных средств
RU2011125366A (ru) 2008-12-05 2013-01-10 Ангиочем Инк. Конъюгаты терапевтических пептидов и их применение
MX2011005965A (es) 2008-12-05 2011-09-01 Angiochem Inc Conjugados de leptina y de análogos de leptina y sus usos de los mismos.
CN102307904A (zh) * 2008-12-05 2012-01-04 安吉奥开米公司 神经降压素或神经降压素类似物的缀合物及其用途
AU2009327267A1 (en) 2008-12-17 2011-07-14 Angiochem, Inc. Membrane type-1 matrix metalloprotein inhibitors and uses thereof
CA2759129C (en) 2009-04-20 2018-12-11 Angiochem Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
US20100284921A1 (en) 2009-05-08 2010-11-11 Temple University - Of The Commonwealth System Of Higher Education Targeted nanoparticles for intracellular cancer therapy
CN102497870A (zh) * 2009-06-03 2012-06-13 戴瑟纳制药公司 肽-dicer底物试剂及其特异性抑制基因表达的方法
CA2764777A1 (en) 2009-06-11 2010-12-16 Angiochem Inc. Fusion proteins for delivery of gdnf and bdnf to the central nervous system
US9161988B2 (en) 2009-07-02 2015-10-20 Angiochem Inc. Multimeric peptide conjugates and uses thereof
HRP20160136T1 (hr) 2009-07-14 2016-03-11 Mayo Foundation For Medical Education And Research Peptidno posredovana ne-kovalentna isporuka aktivnih sredstava kroz krvno moždanu barijeru
WO2011041897A1 (en) 2009-10-06 2011-04-14 Angiochem Inc. Compositions and methods for the transport of therapeutic agents
US9095541B2 (en) 2009-11-24 2015-08-04 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
US8530429B2 (en) * 2009-11-24 2013-09-10 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
EP2333074A1 (en) 2009-12-14 2011-06-15 Robert Steinfeld Substances and methods for the treatment of lysosmal storage diseases
ES2661367T3 (es) 2010-03-08 2018-03-28 Sloan Kettering Institute For Cancer Research Inhibidores de cinasa CDC7 y sus usos
EP2550285B1 (en) * 2010-03-22 2017-07-19 President and Fellows of Harvard College Trioxacarcins and uses thereof
WO2011119608A1 (en) * 2010-03-26 2011-09-29 University Of Tennessee Research Foundation Peptides that specifically target amyloid deposits
US8986689B2 (en) * 2010-04-14 2015-03-24 National Research Council Of Canada Compositions and methods for brain delivery of analgesic peptides
WO2011153642A1 (en) 2010-06-10 2011-12-15 Angiochem Inc. Leptin and leptin analog conjugates and fusion proteins and uses thereof
CA2803646A1 (en) 2010-07-02 2012-01-05 Angiochem Inc. Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
US8218280B2 (en) 2010-07-08 2012-07-10 Schneider Electric USA, Inc. Secondary thermal sensor for primary conductors
US20120156130A1 (en) * 2010-08-06 2012-06-21 Thore Hettmann Use of her3 binding agents in prostate treatment
CN102406949B (zh) 2010-09-21 2013-05-29 复旦大学 一种靶向示踪的多模式诊断纳米影像药物
WO2012037687A1 (en) 2010-09-23 2012-03-29 Angiochem Inc. Therapeutic polypeptides and uses thereof
EP2637669A4 (en) 2010-11-10 2014-04-02 Infinity Pharmaceuticals Inc Heterocyclic compounds and their use
RU2013127625A (ru) 2010-11-18 2014-12-27 Зе Дженерал Хоспитал Корпорейшен Новые композиции и применения антигипертензивных средств для терапии рака
CN102552928A (zh) 2010-12-19 2012-07-11 复旦大学 一种治疗脑部肿瘤的双级靶向递药系统及其制备方法
NZ612909A (en) 2011-01-10 2015-09-25 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones
CN102614105A (zh) 2011-01-28 2012-08-01 复旦大学 一种脑靶向载两性霉素b聚合物胶束给药系统
US20130337051A1 (en) 2011-03-01 2013-12-19 To-Bbb Holding B.V. Advanced active liposomal loading of poorly water-soluble substances
US9238716B2 (en) 2011-03-28 2016-01-19 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
EP2696898A4 (en) 2011-04-07 2014-10-01 Univ Emory COMPOSITIONS WITH SACCHARIDE-BINDING PARTS AND PROCEDURE FOR TARGETED THERAPY
RU2013154422A (ru) 2011-05-09 2015-06-20 Институт Кимик Де Саррия Полимерные наночастицы, предназначенные для доставки лекарственных средств
WO2013004716A1 (en) 2011-07-04 2013-01-10 Universität Basel Peptide beads
TWI565709B (zh) * 2011-07-19 2017-01-11 英菲尼提製藥股份有限公司 雜環化合物及其用途
EP2734520B1 (en) * 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX2014001662A (es) 2011-08-11 2014-08-26 Intellikine Llc Polimeros inhibidores de cinasas.
RU2014111823A (ru) 2011-08-29 2015-10-10 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения и их применения
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
WO2013056096A1 (en) 2011-10-13 2013-04-18 Angiochem Inc. Polypeptide-opioid conjugates and uses thereof
EA032088B1 (ru) 2011-10-27 2019-04-30 Массачусетс Инститьют Оф Текнолоджи Аминокислотные производные, функционализованные на n-конце, способные образовывать микросферы, инкапсулирующие лекарственное средство
HK1201271A1 (en) 2011-11-11 2015-08-28 Intellikine, Llc Kinase inhibitor polymorphs
EP2785838A4 (en) 2011-12-01 2015-07-01 Angiochem Inc VECTORIZED LYSOSOMAL ENZYME COMPOUNDS
RU2014126482A (ru) 2011-12-01 2016-01-27 Ангиочем Инк. Нацеленные соединения ферментов и их применение
HUE052136T2 (hu) * 2011-12-13 2021-04-28 Engeneic Molecular Delivery Pty Ltd Bakteriális eredetû intakt minisejtek terápiás szerek agydaganatokba történõ bejuttatására
CA2859205A1 (en) 2011-12-16 2013-06-20 Massachusetts Institute Of Technology Alpha-aminoamidine polymers and uses thereof
WO2013120107A1 (en) 2012-02-09 2013-08-15 University Of Rochester Methods and compositions for treating a subject to inhibit hearing loss
US20150037281A1 (en) 2012-03-02 2015-02-05 Icahn School Of Medicine At Mount Sinai Variants of prothymosin alpha and methods of using same
SI2833905T1 (en) 2012-04-04 2018-08-31 Halozyme, Inc. Combination therapy with hyaluronidase and tumane-directed taxane
US9745334B2 (en) 2012-04-26 2017-08-29 Yale University Cytotoxic-drug delivering molecules targeting HIV (CDM-Hs), cytotoxic activity against the human immunodeficiency virus and methods of use
CA2876525A1 (en) 2012-06-15 2013-12-19 Angiochem Inc. Targeted iduromdase compounds

Also Published As

Publication number Publication date
EP1583562B1 (en) 2011-06-15
SI1583562T1 (sl) 2011-10-28
CA2516056C (en) 2012-05-29
JP4903036B2 (ja) 2012-03-21
ATE512674T1 (de) 2011-07-15
AU2004203682A8 (en) 2009-09-17
AU2009251223A1 (en) 2010-01-28
DK1583562T3 (da) 2011-09-19
EP2260874A1 (en) 2010-12-15
CN1747747B (zh) 2012-09-05
WO2004060403A3 (en) 2004-11-18
CA2516056A1 (en) 2004-07-22
EP1583562A2 (en) 2005-10-12
BRPI0406647A (pt) 2005-12-06
CN1747747A (zh) 2006-03-15
MXPA05007322A (es) 2006-02-17
AU2004203682A1 (en) 2004-07-22
JP2012031197A (ja) 2012-02-16
WO2004060403A2 (en) 2004-07-22
AU2004203682B2 (en) 2009-10-01
AU2009251223B2 (en) 2012-02-09
US20060182684A1 (en) 2006-08-17
JP2006515363A (ja) 2006-05-25
CY1111844T1 (el) 2015-10-07
ES2368941T3 (es) 2011-11-23
CN102775472A (zh) 2012-11-14
US9221867B2 (en) 2015-12-29

Similar Documents

Publication Publication Date Title
PT1583562E (pt) Angiopep-1, compostos relacionados, e suas utilizações
TWI328576B (en) Diketohydrazine derivative compound, medicament containing same as active ingredient
SI1767535T1 (sl) Sinteza epotilonov njihovih intermediatov analogov in uporaba le teh
AU2003211042A8 (en) Use of buckysome or carbon nanotube for drug delivery
TWI347196B (en) Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
IN2015DN01132A (enExample)
EP1490090A4 (en) SYSTEMS FOR DELIVERING ACTIVE AGENTS AND METHODS FOR PROTECTING AND DELIVERING ACTIVE AGENTS
PL372084A1 (en) 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
WO2006136606A3 (en) Oxindole derivatives
ZA200603538B (en) P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same
HUP0400155A3 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
IL169184A0 (en) Aromatic compounds as anti-inflammatory, immunomdulatory and anti-proliferatory agents
EP2077111A4 (en) ANTIDEPRESSANT
TW200602295A (en) Organic compounds
WO2006072070A3 (en) Pharmaceutical formulations of gallium salts
WO2005084222A3 (en) Synthesis of epothilones, intermediates thereto, analogues and uses thereof
EP1451182A4 (en) DIMERE COMPOUNDS AND THEIR USE AS ANTIVIRAL AGENTS
TW200501970A (en) Use of PVP-iodine liposomes for treatment of acne
TW200509987A (en) Use of PVP-iodine liposomes for treatment of Herpes
WO2002072146A3 (en) Combination of nateglinide or repaglinide with at least one further antidiabetic compound
IS8428A (is) Innrennslislyf sem inniheldur (2R)-2-própýloktansýru sem virka efnisþáttinn
TW200514553A (en) Therapeutic agent for hepatitis C
WO2007110811A3 (en) Use of the staudinger ligation in in vivo assembly of a biologically active compound
ATE461702T1 (de) Krebsmittel
MA28457B1 (fr) Composition fongique comprenant un derive de pyridylethylbenzamide et un compose capable d'inhiber le transport d'electrons de la chaine respiratoire dans des organismes fongiques phytopathogenes